628 related articles for article (PubMed ID: 19289418)
1. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
2. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
3. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA.
Alt K; Wiehr S; Ehrlichmann W; Reischl G; Wolf P; Pichler BJ; Elsässer-Beile U; Bühler P
Prostate; 2010 Sep; 70(13):1413-21. PubMed ID: 20687214
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.
Wiehr S; Bühler P; Gierschner D; Wolf P; Rolle AM; Kesenheimer C; Pichler BJ; Elsässer-Beile U
Prostate; 2014 May; 74(7):743-55. PubMed ID: 24610028
[TBL] [Abstract][Full Text] [Related]
5. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
[TBL] [Abstract][Full Text] [Related]
6. Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA
Maier FC; Wild AM; Kirchen N; Holm F; Fuchs K; Schwenck J; Maurer A; Wiehr S
Appl Radiat Isot; 2019 Jan; 143():149-155. PubMed ID: 30445280
[TBL] [Abstract][Full Text] [Related]
7. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
8. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
9. Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.
D'Souza JW; Hensley H; Doss M; Beigarten C; Torgov M; Olafsen T; Yu JQ; Robinson MK
J Nucl Med; 2017 Jan; 58(1):175-180. PubMed ID: 27539844
[TBL] [Abstract][Full Text] [Related]
10. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
12. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
[TBL] [Abstract][Full Text] [Related]
13. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
14. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.
Cai W; Ebrahimnejad A; Chen K; Cao Q; Li ZB; Tice DA; Chen X
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2024-36. PubMed ID: 17673999
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of
Banerjee SR; Kumar V; Lisok A; Plyku D; Nováková Z; Brummet M; Wharram B; Barinka C; Hobbs R; Pomper MG
J Nucl Med; 2019 Mar; 60(3):400-406. PubMed ID: 30237212
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of a
Jadvar H; Chen K; Park R; Yap LP; Vorobyova I; Swenson S; Markland FS
Amino Acids; 2019 Nov; 51(10-12):1569-1575. PubMed ID: 31621030
[TBL] [Abstract][Full Text] [Related]
19. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
